Home

Alivus Life Sciences Ltd PE Ratio

Image

Alivus Life Sciences Ltd

NSE: ALIVUS

PE

28.4

Last updated on: Mar 16, 2025

Key Highlights

  • The P/E Ratio of Alivus Life Sciences Ltd is 28.4 as of 16 Mar 15:30 PM .
  • The P/E Ratio of Alivus Life Sciences Ltd changed from 13.4 on March 2022 to 20.2 on March 2024 . This represents a CAGR of 14.66% over 3 years.
  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1006 as of 11 Mar 11:21 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.2. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 37.1 in 2024.

Historical P/E Ratio of Alivus Life Sciences Ltd

No data available

Company Fundamentals for Alivus Life Sciences Ltd

Image

Alivus Life Sciences Ltd

NSE: ALIVUS

Share Price

₹ 1006.45

-28.65 (-2.77%)

stock direction

Last updated on: Mar 11, 2025

Market Price of Alivus Life Sciences Ltd

1M

1Y

3Y

5Y

Monitoring Alivus Life Sciences Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
13 Mar 20251023.9
12 Mar 20251020.25
11 Mar 2025986.15
10 Mar 20251035.1
07 Mar 20251078.65
06 Mar 20251062.75
05 Mar 20251023.2
04 Mar 20251022.7
03 Mar 2025935.35
28 Feb 2025885.55

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

che

Weakness

2

che

Opportunity

1

che

Threats

0

che

BlinkX Score for Alivus Life Sciences Ltd

Asset Value vs Market Value of Alivus Life Sciences Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Alivus Life Sciences Ltd12546
Sun Pharmaceuticals Industries Ltd404012
Divis Laboratories Ltd149188
Cipla Ltd118041
Torrent Pharmaceuticals Ltd103507
Dr Reddys Laboratories Ltd92444

PE Ratio of Alivus Life Sciences Ltd Explained

12546

Market cap

441

Earnings

28.4X

PE Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Alivus Life Sciences Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Alivus Life Sciences Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Alivus Life Sciences Ltd

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018.
  • A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited.
  • The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.

Alivus Life Sciences Ltd News Hub

Glenmark Life Sciences Ltd leads gainers in 'A' group

Tamilnad Mercantile Bank Ltd, Marico Ltd, Rossari Biotech Ltd and Nestle India Ltd are among the oth

Read more

05 Aug 24

Glenmark Life Sciences AGM scheduled

Glenmark Life Sciences announced that the Annual General Meeting (AGM) of the company will be held o

Read more

06 Sept 24

Glenmark Life drops after PAT slides 20% YoY to Rs 95 crore in Q2

Profit before tax (PBT) dropped 19.8% YoY to Rs 127.46 crore in the quarter ended 30 September 2024.

Read more

25 Oct 24

Glenmark Life Sciences standalone net profit declines 19.72% in the September 2024 quarter

Net profit of Glenmark Life Sciences declined 19.72% to Rs 95.32 crore in the quarter ended Septembe

Read more

25 Oct 24

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Alivus Life Sciences Ltd

What is the current PE Ratio of Alivus Life Sciences Ltd?

The Current PE Ratio of Alivus Life Sciences Ltd is 28.4 as on 16 Mar 2025.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 16 Mar 2025.

What was the PE Ratio of Alivus Life Sciences Ltd last year?

The PE Ratio of Alivus Life Sciences Ltd was 10.28 last year, now the PE ratio is 28.4, showing a year-on-year growth of 176.3%.

What does the PE Ratio of Alivus Life Sciences Ltd indicate about its stock?

The PE Ratio of Alivus Life Sciences Ltd is 28.4. This ratio indicates that investors are willing to pay 28.4 times the earnings per share for each share of Alivus Life Sciences Ltd.

What is the PE Ratio Growth of Alivus Life Sciences Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Alivus Life Sciences Ltd grew by 176.3% whereas, the EPS ratio grew by 43.7.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions